Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

Exclusion Criteria

• •New York Heart Association class III or IV heart failure or left ventricular ejection fraction \< 30%
• •Have been hospitalized for Heart Failure within 5 years prior to screening
• •Had non-fatal MI, non-fatal stroke, non-elective coronary revascularization and/or hospitalization for unstable angina or chest pain within past 3 months prior to screening
• •Uncontrolled hypertension
• •Diagnosis of homozygous familial hypercholesterolemia (HoFH)
• •Active liver disease
• •HbA1c ≥10%
• •Thyroid Stimulating Hormone (TSH) \> 1.5 times upper limit normal
• •Creatine kinase \> 3 times upper limit normal
• •History of malignancy with surgery in past 3 years
• •History of alcohol or drug abuse within past 5 years
• •Received treatment with investigational product or device within past 30 days excluding Coronavirus treatment or vaccine
• •Known allergy to study drug
• •Participated in previous obicetrapib trial
• •Taking gemfibrozil within 30 days screening